EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel‐modulating antiseizure medications

Russell Nightscales iD, Sarah Barnard iD, Juliana Laze, Zhibin Chen iD, Gerard Tao, Clarissa Auvrez, Shobi Sivathamboo, Mark J Cook, Patrick Kwan iD, Daniel Friedman, Samuel F Berkovic iD, Wendyl D'Souza und 3 weitere

Epilepsia Open · 2023-06 · 8 (2) · 334-345

DOI: 10.1002/epi4.12693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, online erschienen am 15.02.2023. Verfasst von Russell Nightscales und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Sudden Unexpected Death in Epilepsy, Epilepsy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In vitro data prompted U.S Food and Drug Administration warnings that lamotrigine, a common sodium channel modulating anti‐seizure medication (NaM‐ASM), could increase the risk of sudden death in patients with structural or ischaemic cardiac disease, however, its implications for Sudden Unexpected Death in Epilepsy (SUDEP) are unclear.

Methods

This retrospective, nested case–control study identified 101 sudden unexpected death in epilepsy (SUDEP) cases and 199 living epilepsy controls from Epilepsy Monitoring Units (EMUs) in Australia and the USA. Differences in proportions of lamotrigine and NaM‐ASM use were compared between cases and controls at the time of admission, and survival analyses from the time of admission up to 16 years were conducted. Multivariable logistic regression and survival analyses compared each ASM subgroup adjusting for SUDEP risk factors.

Results

Proportions of cases and controls prescribed lamotrigine ( P = 0.166), one NaM‐ASM ( P = 0.80), or ≥2NaM‐ASMs ( P = 0.447) at EMU admission were not significantly different. Patients taking lamotrigine (adjusted hazard ratio [aHR] = 0.56; P = 0.054), one NaM‐ASM (aHR = 0.8; P = 0.588) or ≥2 NaM‐ASMs (aHR = 0.49; P = 0.139) at EMU admission were not at increased SUDEP risk up to 16 years following admission. Active tonic–clonic seizures at EMU admission associated with >2‐fold SUDEP risk, irrespective of lamotrigine (aHR = 2.24; P = 0.031) or NaM‐ASM use (aHR = 2.25; P = 0.029). Sensitivity analyses accounting for incomplete ASM data at follow‐up suggest undetected changes to ASM use are unlikely to alter our results. Significance This study provides additional evidence that lamotrigine and other NaM‐ASMs are unlikely to be associated with an increased long‐term risk of SUDEP, up to 16 years post‐EMU admission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sudden Unexpected Death in EpilepsyEpilepsyUnited StatesHumansLamotrigineCase-Control StudiesRetrospective StudiesAnticonvulsantsDeath, Sudden

Substanzen

LamotrigineAnticonvulsants

Autor:innen und Institutionen

  • Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • Department of Neurology, Alfred Health, Melbourne, Victoria, Australia.
  • Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
  • Clinical Epidemiology, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Department of Medicine (The Royal Melbourne Hospital), The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

ORCID-Profile: Russell Nightscales, Sarah Barnard, Zhibin Chen, Patrick Kwan, Samuel F Berkovic, Piero Perucca, Orrin Devinsky

Zitieren

APA

Nightscales, R., Barnard, S., Laze, J., Chen, Z., Tao, G., Auvrez, C., Sivathamboo, S., Cook, M. J., Kwan, P., Friedman, D., Berkovic, S. F., D'Souza, W., Perucca, P., Devinsky, O., & O'Brien, T. J. (2023). Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel‐modulating antiseizure medications. Epilepsia Open, 8(2), 334-345. https://doi.org/10.1002/epi4.12693

Vancouver

Nightscales R, Barnard S, Laze J, Chen Z, Tao G, Auvrez C, et al. Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel‐modulating antiseizure medications. Epilepsia Open. 2023;8(2):334-345. doi:10.1002/epi4.12693

BibTeX
@article{Nightscales2023,
  author = {Nightscales, Russell and Barnard, Sarah and Laze, Juliana and Chen, Zhibin and Tao, Gerard and Auvrez, Clarissa and Sivathamboo, Shobi and Cook, Mark J and Kwan, Patrick and Friedman, Daniel and Berkovic, Samuel F and D'Souza, Wendyl and Perucca, Piero and Devinsky, Orrin and O'Brien, Terence J},
  title = {Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel‐modulating antiseizure medications},
  journal = {Epilepsia Open},
  year = {2023},
  volume = {8},
  number = {2},
  pages = {334--345},
  doi = {10.1002/epi4.12693}
}
Kostenlos starten →